Gentium S.p.A. Announces Successful Completion Of Defibrotide Phase 1 Study In Japan

Published: Nov 12, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VILLA GUARDIA (COMO), Italy, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the medical team from the Phase 1 Trial Unit of the Translational Research Center at the National University Corporation, Hamamatsu University School of Medicine ("HUSM"), Fukushima Medical University ("FMU") has successfully completed the phase 1 clinical study to evaluate the Safety and Pharmacokinetics of Defibrotide (DF) in Healthy Adults.

Help employers find you! Check out all the jobs and post your resume.

Back to news